SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

Search

Orion Oyj (Class B)

Отворен

56.84 4.06

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

54.6

Максимум

56.84

Ключови измерители

By Trading Economics

Приходи

-128M

73M

Продажби

-37M

434M

P/E

Средно за сектора

23.345

63.778

EPS

0.52

Дивидентна доходност

2.99

Марж на печалбата

16.897

Служители

3,880

EBITDA

136M

202M

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.99%

2.39%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

2.1B

7.7B

Предишно отваряне

52.78

Предишно затваряне

56.84

Orion Oyj (Class B) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2025 г., 23:55 ч. UTC

Горещи акции

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2.04.2025 г., 22:50 ч. UTC

Значими двигатели на пазара

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2.04.2025 г., 21:08 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2.04.2025 г., 21:00 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2.04.2025 г., 23:56 ч. UTC

Пазарно говорене

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Топ новини

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2.04.2025 г., 23:10 ч. UTC

Пазарно говорене

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:57 ч. UTC

Пазарно говорене

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2.04.2025 г., 22:43 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2.04.2025 г., 22:12 ч. UTC

Пазарно говорене

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2.04.2025 г., 21:48 ч. UTC

Топ новини

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2.04.2025 г., 21:41 ч. UTC

Пазарно говорене

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2.04.2025 г., 21:04 ч. UTC

Топ новини

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2.04.2025 г., 21:03 ч. UTC

Пазарно говорене

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2.04.2025 г., 20:53 ч. UTC

Печалби

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2.04.2025 г., 20:52 ч. UTC

Печалби

Kaiser Aluminum Changes Inventory Acctg Methodology

Сравнение с други в отрасъла

Ценова промяна

Orion Oyj (Class B) Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.